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Abstract 
Background: Clinical evaluation of male lower urinary tract symptoms (MLUTS) in secondary 
care uses a range of assessments. It is unknown how MLUTS evaluation influences outcome 
of therapy recommendations and choice, notably urodynamics (UDS; filling cystometry and 
pressure flow studies).  
Objective: Report the participant sociodemographic and clinical characteristics, and initial 
diagnostic findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of 
Assessment Methods (UPSTREAM). UPSTREAM is a randomised controlled trial evaluating 
whether symptoms are non-inferior and surgery rates are lower if UDS is included. 
Design, Setting, and Participants: 820 men (≥18-years) seeking treatment for bothersome 
LUTS recruited from 26 NHS hospital urology departments.  
Intervention: Care pathway based on routine, non-invasive tests (control) or routine care 
plus UDS (intervention arm).  
Outcome Measurements: Primary outcome is International Prostate Symptom Score (IPSS) 
and key secondary outcome is surgery rates, 18-months after randomisation. International 
Consultation on Incontinence Questionnaires (ICIQ) were captured for MLUTS, sexual 
function and UDS satisfaction.  
Statistical Analysis: Baseline clinical and patient reported outcomes (PROMs), and UDS 
findings, were informally compared between arms. Trends across age groups for urinary and 
sexual PROMs were evaluated with a Cuzick’s test and questionnaire items compared using 
Pearson’s correlation coefficient.  
Results and Limitations: Storage LUTS, notably nocturia, and impaired sexual function are 
prominent in men being assessed for surgery. Sociodemographic and clinical evaluations 
were similar between arms. Overall mean IPSS and quality of life scores were 18.94 and 
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4.13, respectively. Trends were found across age groups, with older men suffering from 
higher rates of incontinence, nocturia and erectile dysfunction and younger men suffering 
from increased daytime frequency and voiding symptoms. Men undergoing UDS expressed 
high satisfaction with the procedure.  
Conclusions: Men being considered for surgery have additional clinical features that may 
affect treatment decision-making and outcomes, notably storage LUTS and impaired sexual 
function.  
 
Patient Summary: We describe initial assessment findings from a large clinical study of the 
treatment pathway for men suffering with bothersome urinary symptoms referred to 
hospital for further treatment, potentially including surgery. We report the patient 
characteristics and diagnostic test results, including symptom questionnaires, bladder 
diaries, flow rate tests and urodynamics. 
1. Introduction 
Male lower urinary tract symptoms (MLUTS) are common; the prevalence increases with 
age, they can have detrimental impact on quality of life (QoL), and are associated with 
considerable personal and societal costs [1-4]. Various causative mechanisms can 
contribute, so proper assessment is needed to aid diagnosis and guide treatment decision-
making. Benign prostate enlargement (BPE), causing partial bladder outlet obstruction 
(BOO), can cause voiding LUTS (slow stream, hesitancy, straining) and post-voiding LUTS 
(post-micturition dribble (PMD) and sensation of incomplete emptying). In such cases 
prostate surgery, such as a transurethral resection of the prostate (TURP), is commonly 
considered. Another cause of voiding LUTS, however, is declining strength of the bladder 
(detrusor underactivity; DU), where prostate surgery is unlikely to improve symptoms [5] 
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and would expose men to associated risks (e.g. sexual side effects or incontinence). This is, 
however, an area where inconsistent findings have been reported [6, 7]. Co-existing storage 
LUTS (urgency, increased daytime voiding frequency, urgency incontinence and nocturia), 
including overactive bladder syndrome (OAB) also do not improve reliably after surgery to 
relieve BOO [8]. Nocturia is further complicated by behavioural and systemic factors 
influencing urine production, and giving rise to nocturnal polyuria (NP) [9]. Since any 
combination of BOO, DU, OAB and NP can be present in a given individual, accurate 
assessment is essential.  
Typically, men with LUTS should undergo the following ‘routine’ assessments: (1) medical 
history to establish which LUTS are present and their QoL impact, relevant comorbidities, 
medications and lifestyle, sexual function and the man’s perspectives regarding LUTS and 
treatment options; (2) bladder diary (≥3-days); (3) validated symptom score questionnaires; 
(4) urinalysis; (5) digital rectal examination (DRE); and (6) uroflowmetry (maximum flow rate 
(Qmax), voided volume (VV) and post void residual (PVR)) [10, 11]. 
Invasive urodynamics (UDS) is the only test, however, able to distinguish between BOO and 
DU, by finding slow Qmax with abnormal increase or reduction of detrusor pressure 
respectively, as expressed by the BOO Index (BOOI) and Bladder Contractility Index (BCI). 
UDS also identifies storage phase dysfunction, notably detrusor overactivity (DO). A high 
BOOI (>40) with a normal BCI (>100) and absence of DO seemingly represent the most 
suitable UDS features to consider surgery for BOO. However, literature reviews over the last 
decade identified there is no robust, high-level clinical evidence to support use of UDS 
routinely (as opposed to selectively) for MLUTS [11-13]. Thus, UDS is generally used as an 
‘optional’ test in UK practice, at the discretion of the responsible clinician.  
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UPSTREAM is a randomised controlled trial (RCT) in the context of the care pathway from 
urological presentation with LUTS to outcome of therapy [14], using the full set of routine 
assessments, and randomising half of the participants to additional assessment with UDS. 
The study’s main outcomes will be reported in 2019, and are expected to have significant 
implications for the management of LUTS in secondary care. Here, we report baseline 
characteristics and the initial diagnostic testing outcomes for the study.  
 
2. Material (Patients) and Methods 
2.1. Study design and participants 
Details of background and design are published elsewhere [14, 15]. In brief, UPSTREAM is a 
two-arm, multicentre RCT, that randomised eligible men between care pathways using 
routine care with UDS or without it. The design was utilised to establish non-inferiority in 
symptom severity 18-months after randomisation [15]. The primary outcome is 
International Prostate Symptom Score (IPSS) at 18-months, and the key secondary outcome 
is the influence of UDS on rates of bladder outlet surgery. The setting is urology 
departments of 26 National Health Service (NHS) hospitals throughout England. Men (≥18-
years) seeking further treatment for bothersome LUTS, which may include surgery were 
invited to participate. Men were excluded if they required a catheter to pass urine, had a 
relevant neurological disease, were undergoing treatment for prostate or bladder cancer, 
had previously had prostate surgery, were medically unfit for surgery, and/or were unwilling 
to be randomised or comply with trial requirements. The study also assesses cost-
effectiveness and includes detailed qualitative research [16].  
 
2.2. Trial registration and ethics 
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The study was registered with the ISRCTN registry, 8 April 2014 (ISRCTN56164274). The 
National Research Ethics Service Committee South Central – Oxford B reviewed and 
approved the study, 10 July 2014 (reference 14/SC/0237). 
 
2.3. Outcome measures 
Data collection occurred between October 2014 and August 2018. Outcome measures, 
including components and timings, are detailed elsewhere [14, 15].  
 
2.3.1. Sociodemographic and clinical outcomes 
Sociodemographic characteristics (e.g. age, ethnicity, and postal code (i.e. geographical 
identifier) and clinical outcomes (e.g. comorbidities, DRE, uroflowmetry, UDS and additional 
tests) were collected via case report forms completed by trained hospital (centre) staff. Key 
clinical outcomes were followed up at subsequent appointments through to 18-months 
after randomisation [14]. For all men who underwent UDS, filling cystometry and pressure 
flow voiding data were collected. Procedures of UDS testing and quality control assessment 
were as stated in the International Continence Society Standards [14].  
 
2.3.2. Patient-reported outcome measures (PROMS) 
PROMS captured at 0- (baseline), 6-, 12- and 18-months included the IPSS [17], International 
Consultation on Incontinence Questionnaire for MLUTS (ICIQ-MLUTS) and associated sexual 
matters (ICIQ-MLUTSsex) (see Supplementary Material 1). ICIQ 3-day bladder diaries were 
completed at baseline and 18-months. Men who underwent UDS were asked to complete 
the ICIQ-UDS-Satisfaction questionnaire. Copies of ICIQ materials can be requested via the 
website: www.iciq.net [18].  
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2.4. Statistical analysis 
The database was locked prior to final data analysis, as described elsewhere [15]. Data 
presented are n (%) or mean (standard deviation (SD)) unless otherwise stated. Any missing 
baseline data is due to missing/incomplete questionnaires, and men who withdrew fully 
from the study. Baseline characteristics were considered imbalanced if they met a pre-
specified absolute difference of 10% or 0.5 SDs between arms. Measurements taken at UDS 
have been separated by arm, as some patients deviated from their initial randomised 
allocation. However, no formal comparisons were made between the arms.  
For exploratory baseline analysis, urinary and sexual symptoms were compared across age 
categories (<55, 55-64, 65-74, ≥75-years) using logistic regression and Cuzick’s test for trend. 
Categorical outcomes were dichotomised for ease of reporting and to aid interpretation. As 
seen in previous studies [19], to aid clinical interpretation, daytime frequency was broken 
down into ≤8 times per day versus >8 times per day, and men were considered to have 
nocturia if they were getting up to urinate more than once per night. Sexual function was 
considered impaired if a man scored one or more for any of the four symptom questions in 
the ICIQ-MLUTSsex PROM. When comparing the IPSS and ICIQ questions, a Pearson’s 
correlation coefficient was calculated along with its associated p-value. Analyses were 
performed using STATA 15.1 [20].  
 
3. Results 
3.1. Recruitment  
Supplementary Material 2 details recruitment to the study, including assessment for 
eligibility (screening) data. Between October 2014 and December 2016, 8671 patient 
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referrals and notes were scrutinised to identify suitable men to invite to take part in the 
study; 5910 (68%) were considered ineligible and reasons for non-inclusion were 
unidentified for 1279 (15%). Of the 1482 (17%) considered eligible, 820 (55%) were 
randomised (enrolled; 427 in the UDS arm and 393 in the routine care arm) and 662 (45%) 
declined to take part (see Supplementary Material 2). 
 
3.2. Sociodemographic and clinical characteristics 
Table 1 reports the study baseline sociodemographics. Men were predominantly of white 
ethnicity (92%) with a median social deprivation index score of 14 (range from 0-78; full 
range of scale 0-100). Median age was 68-years, with an interquartile range (IQR) of 62-74 
and overall range of 22-91. Many patients (67%) had comorbidities at baseline; 27% 
(215/803) had one comorbidity, 19% (156/803) two and 21% (170/803) more than two.  
Table 2 reports the baseline clinical characteristics and PROMS. Approximately 78% of the 
cohort had a benign enlargement based on DRE findings. Although 70% did not have 
additional discretionary tests at baseline, common additional procedures were PSA testing 
(14%) and cystoscopy (9%). The median Qmax was 10.8 ml/s (IQR 7.6-15.0), PVR 100 ml (IQR 
44-182) and VV 214 ml (IQR 143-316).  
 
3.3. Patient reported outcome measures (PROMs) 
3.3.1. QoL, urinary symptoms, sexual function and bladder diaries 
Mean IPSSs were 18.52 and 19.39 for the UDS and routine care arms, respectively. The 
median IPSS QoL score was four (mean=4.13), which corresponds to ‘mostly dissatisfied’ on 
the scale of delighted (zero) – terrible (six).  
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Almost half of the cohort were urinating more than eight times per day, on average. 
Nocturia prevalence was high, with 78% of men getting up to urinate more than once per 
night. Completion of baseline ICIQ-MLUTSsex was ~90%, and 67% percent of men reported 
that urinary symptoms were affecting their sex life. Only 26% could achieve an erection with 
normal rigidity and only 20% had a normal quantity of ejaculation. All urinary and sexual 
symptoms were well balanced at baseline with a maximum absolute difference of 5% or 0.2 
SDs between arms. The median time between baseline questionnaire completion and 
randomisation was 0-days (IQR range 0, 0), but for 38 men, baseline questionnaires were 
completed outside a six month window from the randomisation date. Completion of all 
three days on the bladder diaries was relatively poor (~25%) but, of those fully completed, 
data was balanced between arms. Supplementary Material 3 presents an overview of 
baseline bladder diary completion rates. 
 
3.3.2. Symptoms by age group 
There was a strong association of age group with almost all symptoms (Table 3). Sexual 
symptoms concerning quality of erections/ejaculations were much worse for older men. 
Fifty percent of men aged <55-years suffered from reduced erections compared with 93% of 
≥75-year olds, with a similar difference for reduced ejaculation. Using the ICIQ-MLUTS 
questionnaire we found that younger age groups had higher voiding scores (p<0.001) 
whereas older age groups suffered from higher incontinence scores (generally reflecting 
storage LUTS rather than actual incontinence) (p=0.003). For urinary frequency, getting up 
to urinate more than once per night (nocturia) was higher in older men whereas daytime 
frequency (>8-times) was higher in younger men. Overall IPSS and QoL was slightly better 
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(lower) for older age groups but statistical evidence was limited. For individual symptoms, 
urgency and strength of stream were similar across age groups. 
 
3.3.3. Cross-checking IPSS with ICIQ-MLUTS 
Comparing responses of the IPSS questionnaire with the equivalent ICIQ-MLUTS questions, 
all answers were highly correlated (p<0.001) (Table 4). Nocturia had the highest correlation 
coefficient (r=0.86); however, 141/770 (18%) of the respondents gave conflicting answers, 
despite similarity of the two items. Daytime frequency had the lowest correlation coefficient 
(r=0.44). Storage symptoms were more bothersome than voiding symptoms, measured 
using the ICIQ-MLUTS questionnaire. The most bothersome symptoms were nocturia and 
urgency, with mean scores of 5.85 and 5.78, respectively, out of ten. Completion rates for 
the PROMs were 93-96%. Completion of the ICIQ-MLUTS questions related to individual 
symptom bother was generally good (88-94%) but lower than the corresponding questions 
on symptom severity.  
 
3.3.4. UDS satisfaction 
The ICIQ-UDS-Satisfaction questionnaire identified the median satisfaction score to be ten 
out of ten, indicating very high overall satisfaction with UDS assessment (Table 5). Data was 
also obtained from 28 men in the routine care arm who underwent UDS. Fifty percent of 
men scored the test to be better than expected, and conversely 26% said it was worse than 
expected. Generally, components of the UDS evaluation were scored very favourably, 
although 11% reported dissatisfaction with the explanation of the results. 
 
3.4. UDS data  
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The number allocated to receive UDS was 427, with 353 (83%) actually doing so. The 
number allocated to routine care was 393, however, 28 (7%) of these men went on to 
receive UDS. Further details on the reasons for deviating from assigned allocation can be 
found in Supplementary Material 2. The median BOOI and BCI for the UDS arm were 48 and 
112 respectively. For those initially allocated to non-UDS but who received UDS, BOOI was 
55 and BCI was 114 (Table 6). DO was seen in 52% of men in the UDS arm and 64% of men in 
the non-UDS arm.  
 
4. Discussion 
This large secondary care dataset (820 men across 26 secondary care urology centres) 
provides a unique insight into MLUTS, and study results will address an identified lack of 
robust evidence for impact of UDS assessment on outcome [11-13]. The overall level of 
symptom severity on IPSS was 18.94, which is slightly low compared with studies of surgical 
interventions, probably because the study baseline is taken from the start of the secondary 
care diagnostic pathway, rather than at the time of intervention. For example, the range of 
mean baseline IPSSs from four surgery meta-analyses were 15.80 to 27.90 [21-24].  
The target population is men being assessed to decide whether surgery would be suitable. 
Many men solely reported storage LUTS, or described them as the main source of bother. 
This reflects everyday reality of referral, but is a concern since outcomes of surgery to treat 
BOO are less reliable where storage LUTS are problematic [25]. In particular, nocturia was 
highly prevalent and bothersome (IPSS, ICIQ-MLUTS and bladder diary), yet nocturia often 
reflects systemic conditions unrelated to LUTS [9]. Consequently, evaluations must identify 
where systemic factors could be relevant; the only test that would identify it in standard 
LUTS pathways is the bladder diary (by discerning a high nocturnal polyuria index), yet we 
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found that only 25% fully completed all days and nights of a 3-day diary, even under the 
optimal conditions of a well-supported clinical trial. Supporting data presents a real-life 
experience of how difficult it is to persuade people to complete bladder diaries. As with 
storage LUTS, the issue of sexual function needs to be discussed, as identified in EAU 
Guidelines [10], and observing that impaired sexual function affects two thirds of men at 
baseline shows how the issue is pertinent.  
Of those considered eligible, 55% agreed to take part, similar to our previous studies [26]. 
Completion rates for PROMs were good, including 94% full completion at baseline of the 
IPSS. By including the ICIQ-MLUTS questionnaire we captured symptoms not measured by 
IPSS (notably PMD and incontinence), and the bother caused by individual symptoms. This 
showed that the two PROMs perform differently, with some items generating rather 
different results for equivalent components, notably increased daytime voiding frequency. 
Future analysis will additionally review bladder diary parameters to corroborate the PROMs 
reporting and identify which provided a better reflection of the diary findings. We identified 
where additional ‘discretionary’ tests were done, with PSA testing (14%) the most common. 
This value reflects PSA testing done in secondary care, additional to preceding tests done in 
primary care, which is where most such testing would usually be undertaken. Data on 
primary care PSA testing was not captured in the study. 
There was crossover between arms, with 83% of men randomised to UDS receiving it, and 
conversely 28 men from the routine care arm undergoing UDS. A variety of reasons for this 
was identified and, underlying, it is likely a reflection of anxieties and preconceptions 
experienced by patients and healthcare professionals. In the UDS arm, overall BOOI was 48 
(>40 indicates obstruction) and BCI was 112 (>100 is good contractility), with similar results 
for men in the routine care arm also receiving UDS. Since flow rate findings were very 
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similar between the arms, and symptoms were likewise well-matched, we hypothesise that 
UDS characteristics probably would have been similar if they had been measured in the 
entire routine care arm. Satisfaction with UDS overall was high, and indicates several 
elements which were explored in previously published qualitative research from the 
UPSTREAM trial [16].  
The UPSTREAM trial will evaluate whether a treatment pathway that includes UDS is non-
inferior to the standard (routine care) pathway for men eligible for surgery. It will determine 
whether UDS should change from being an optional test in routine assessment of male 
LUTS, and additionally scrutinise the contribution of each diagnostic test in the care 
pathway. The protocol and analysis plan were published before recruitment end [14, 15].  
The dataset is a real-life reflection of referral, but the context means that completion rates 
for many assessments is higher than everyday clinical experience.  
 
5. Conclusions 
UPSTREAM is a large RCT of MLUTS looking at the full pathway of assessment and 
treatment, randomising between routine care and routine care plus UDS. Arms are well-
matched in terms of sociodemographic, baseline and initial test responses. The results 
presented reflect a real-life population in which storage LUTS and impaired sexual function 
are prevalent, which are key considerations for men under assessment for potential use of 
surgery as part of therapy.   
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Take Home Message 
Men being considered for surgery have additional clinical features that may affect 
treatment decision-making and outcomes, notably storage LUTS and impaired sexual 
function. Sociodemographic and clinical evaluations were similar between arms. Overall 
mean IPSS and quality of life scores were 18.94 and 4.13. Men undergoing UDS expressed 
high satisfaction with the procedure.  
Table 1. Baseline sociodemographics of men randomised (enrolled) to the UPSTREAM trial 
  Urodynamics  Routine care 
 na Mean (SD) or n (%) na Mean (SD) or n (%) 
Total number of participants 427  393  
Age(years) 424 67.51 (9.59) 389 67.81 (8.79) 
Hospital (Centre)b 
1  56 (13%)  58 (15%) 
2  12 (3%)  20 (5%) 
3  35 (8%)  27 (7%) 
4  29 (7%)  26 (7%) 
5  29 (7%)  18 (5%) 
6  5 (1%)  4 (1%) 
7  17 (4%)  9 (2%) 
8  9 (2%)  12 (3%) 
9  17 (4%)  14 (4%) 
10  11 (3%)  6 (2%) 
11  8 (2%)  7 (2%) 
12  16 (4%)  17 (4%) 
13 
427 
15 (4%) 
393 
11 (3%) 
14 17 (4%) 19 (5%) 
15  14 (3%)  13 (3%) 
16  21 (5%)  23 (6%) 
17  24 (6%)  13 (3%) 
18  14 (3%)  12 (3%) 
19  3 (1%)  6 (2%) 
20  15 (4%)  16 (4%) 
21  13 (3%)  13 (3%) 
22  9 (2%)  7 (2%) 
23  13 (3%)  21 (5%) 
24  10 (2%)  9 (2%) 
25  11 (3%)  9 (2%) 
26  4 (1%)  3 (1%) 
Ethnicity 
White  377 (91%)  356 (93%) 
Black/African/Caribbean/Black 
British 
 8 (2%)  6 (2%) 
Mixed/Multiple ethnic groups 
415 
17 (4%) 
383 
11 (3%) 
Asian/Asian British 2 (<1%) 1 (<1%) 
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Other ethnic group  3 (1%)  2 (1%) 
Disclosure declined  8 (2%)  7 (2%) 
Index of Multiple Deprivation (IMD) scores 2015 (based on postal codes) 
Median IMD score 2015c 411 14 (8, 12) 383 14 (8, 24) 
Quintile 1 (most deprived)  43 (10%)  61 (16%) 
Quintile 2  75 (18%)  49 (13%) 
Quintile 3  92 (22%)  91 (24%) 
Quintile 4  106 (26%)  86 (22%) 
Quintile 5 (least deprived)  95 (23%)  96 (25%) 
aThe number of men who we have data for (denominator); three men in the urodynamics arm and four men in 
the routine care arm requested for all of their data to be withdrawn, therefore the maximum values are 424 
and 389 respectively (apart from centre), bCentre names have been replaced with numeric identifiers for the 
purpose of reporting, cHigher scores mean higher levels of deprivation (http://geoconvert.mimas.ac.uk) [27] 
  
25 
 
 
 
Table 2. Baseline clinical characteristics of men randomised (enrolled) to the UPSTREAM 
trial 
  Urodynamics  Routine care 
 na Mean (SD) or n (%) na Mean (SD) or n (%) 
Clinical baseline characteristics 
Comorbidities at baseline 420 281 (67%) 383 260 (68%) 
DRE findingsb 
No abnormality 395 108 (27%) 375 120 (32%) 
Benign enlargement 395 312 (79%) 375 287 (77%) 
Suspected prostate cancer 395 16 (4%) 375 8 (2%) 
Other 395 22 (6%) 375 20 (5%) 
Uroflowmetryc 
Maximum flow rate – Qmax (ml/s) 402 10.20 (7.40, 15.00) 371 11.00 (7.90, 58.30) 
Post void residual volume – PVR 
(ml) 
401 100.00 (40.00, 180.00) 373 100.00 (45.00, 
189.00) 
Voided volume - VV (ml) 405 215.00 (133.00, 318.00) 376 214.00 (149.50, 
316.00) 
Additional (discretionary) tests 
PSA test  57 (14%)  57 (15%) 
Cystoscopy  44 (11%)  25 (7%) 
Urea & Electrolytes 413 18 (4%) 383 17 (4%) 
Kidney Ultrasound  14 (3%)  11 (3%) 
Voiding urinary cytology  2 (<1%)  2 (1%) 
Prostate volume measurement  15 (4%)  7 (2%) 
IPSS: Symptom severity at baseline 
Total IPSS 403 18.52 (6.90) 371 19.39 (7.14) 
Incomplete Emptying 411 2.64 (1.71) 379 2.88 (1.72) 
Frequency 411 3.36 (1.35) 379 3.56 (1.30) 
Intermittency 411 2.58 (1.69) 379 2.65 (1.62) 
Urgency 409 2.60 (1.68) 379 2.80 (1.66) 
Weak Stream 409 3.17 (1.57) 379 3.16 (1.61) 
Straining 408 1.56 (1.56) 377 1.67 (1.66) 
Nocturia 410 2.60 (1.32) 379 2.72 (1.28) 
IPSS QoL 411 4.07 (1.36) 379 4.20 (1.25) 
ICIQ MLUTS 
Voiding scored 394 8.88 (4.04) 370 9.30 (4.38) 
Incontinence scoree 395 5.01 (3.37) 369 5.19 (3.27) 
Daytime frequency (>8 times) 398 160 (40%) 374 169 (45%) 
Nocturia (>1 times per night) 398 300 (75%) 374 301 (80%) 
ICIQ MLUTS – sexual matters 
Erections (reduced or none) 389 277 (71%) 362 275 (76%) 
Ejaculation (reduced or none) 383 300 (78%) 359 295 (82%) 
Painful ejaculation (Yes) 359 56 (16%) 343 71 (21%) 
Urinary symptoms affected sex 
life? 
378 259 (69%) 358 233 (65%) 
     
     
     
     
     
Continued over page     
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Bladder Diaryf     
Voiding frequency (voids per 24-
hours) 
106 10.20 (3.37) 99 9.65 (2.93) 
Daytime Frequency 8.38 (2.78) 7.87 (2.41) 
Nocturia Frequency 1.81 (1.26) 1.78 (1.13) 
Maximum voided volume (ml) 334.29 (131.02) 344.41 (132.25) 
Mean 24-hour total voided 
volume (ml) 
1755.96 (628.80) 1780.19 (639.13) 
Nocturnal polyuria index (%) 23.14 (13.20) 22.64 (13.07) 
aThe number of men who we have data for (denominator); three men in the urodynamics arm and four men in 
the routine care arm requested for all of their data to be withdrawn therefore the maximum values are 424 and 
389 respectively (apart from centre), bThese were not treated as mutually exclusive and centre staff were asked 
to tick all that applied, the denominator is the number of men who answered yes/no to at least one finding, cAs 
data was skewed for these outcomes, medians and IQRs are presented dVoiding scale, on a scale of 0-20 with 
larger scores indicating more severe symptoms, eIncontinence scale, on a scale of 0-24 with larger scores 
indicating more severe symptoms, fThe number of men who completed all 3-days of the bladder diary. 
Table 3. Urinary and sexual symptoms by age in the UPSTREAM trial 
 
Age group (years) 
<55 
(N=66) 
55-64 
(N=217) 
65-74 
(N=355) 
≥75 
(N=175) 
P value 
Urinary and sexual 
symptoms 
Mean (SD) 
/n(%) 
Mean (SD) 
/n(%) 
Mean (SD) 
/n(%) 
Mean (SD) 
/n(%) 
 
IPSS (min ‘n’) n=58 n=209 n=342 n=165  
 Incomplete emptying 3.16 (1.53) 2.95 (1.82) 2.66 (1.68) 2.56 (1.69) 0.003a 
 Frequency 3.50 (1.31) 3.67 (1.30) 3.43 (1.32) 3.26 (1.38) 0.010a 
 Intermittency 2.84 (1.78) 2.81 (1.70) 2.50 (1.61) 2.54 (1.64) 0.039a 
 Urgency 2.71 (1.64) 2.65 (1.66) 2.68 (1.66) 2.80 (1.73) 0.450a 
 Weak stream 3.02 (1.55) 3.31 (1.65) 3.09 (1.56) 3.18 1.56) 0.624a 
 Straining 2.16 (1.81) 1.90 (1.75) 1.46 (1.45) 1.38 (1.58) <0.001a 
 Nocturia 2.24 (1.48) 2.45 (1.31) 2.69 (1.24) 2.97 (1.27) <0.001a 
 Total IPSS score 19.62 (6.62) 19.71 (7.57) 18.50 (6.87) 18.61 (6.71) 0.090a 
 IPSS QoL 4.40 (1.36) 4.18 (1.32) 4.06 (1.32) 4.14 (1.27) 0.189a 
      
ICIQ MLUTS (min ‘n’) n=57 n=207 n=332 n=165  
 Voiding score 10.07 (4.37) 9.99 (4.49) 8.79 (3.93) 8.22 (4.11) <0.001a 
 Incontinence score 4.60 (3.38) 4.90 (3.44) 5.02 (3.28) 5.65 (3.17) 0.003a 
 Daytime frequency (>8 
times) 
28 (49%) 109 (52%) 140 (41%) 52 (31%) <0.001b 
 Nocturia (>1 times) 36 (63%) 151 (72%) 269 (80%) 145 (86%) <0.001b 
      
ICIQ MLUTS – sexual 
matters (min ‘n’) 
n=56 n=201 n=313 n=132  
 Erections (reduced or 
none) 
28 (50%) 124 (60%) 253 (77%) 147 (93%) <0.001b 
 Ejaculation (reduced or 
none) 
30 (54%) 149 (72%) 265 (82%) 151 (96%) <0.001b 
 Painful ejaculation 15 (27%) 45 (22%) 51 (16%) 16 (12%) 0.003b 
 Urinary symptoms 
affected sex life? 
34 (61%) 155 (75%) 221 (69%) 82 (54%) 0.006b 
aCuzick’s test for trend, bLogistic regression, min ‘n’ refers to the lowest denominator in the category 
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Table 4. Comparing IPSS and ICIQ MLUTS questionnaires in the UPSTREAM trial 
 
ICIQ IPSS Correlation (IPSS vs ICIQ) ICIQ symptom bother 
score (0-10) 
N Question Scale N Question Scale N R (p value)a N Mean (sd) 
768 Do you strain to 
continue 
urinating? 
Never (0) – 
All of the time (4) 
785 How often have you had 
to strain to start 
urination? 
Not at all (0) – 
Almost always (5) 
762 0.72 (<0.001) 725 3.70 (3.24) 
770 Would you say 
that the strength 
of your urinary 
stream is? 
Normal (0) – 
Reduced all of the 
time (4) 
788 How often have you had 
a weak urinary stream? 
Not at all (0) – 
Almost always (5) 
767 0.73 (<0.001) 759 4.84 (3.13) 
772 Do you stop and 
start more than 
once while you 
urinate? 
Never (0) – 
All of the time (4) 
790 How often have you 
found you stopped and 
started again several 
times when you 
urinated? 
Not at all (0) – 
Almost always (5) 
771 0.69 (<0.001) 751 4.27 (3.10) 
774 How often do you 
feel that your 
bladder has not 
emptied properly 
after you have 
urinated? 
Never (0) – 
All of the time (4) 
790 How often have you had 
the sensation of not 
emptying your bladder 
completely after you 
finish urinating? 
Not at all (0) – 
Almost always (5) 
773 0.71 (<0.001) 759 5.09 (3.17) 
774 Do you have a 
sudden need to 
rush to the toilet 
to urinate? 
Never (0) – 
All of the time (4) 
788 How often have you 
found it difficult to 
postpone urination? 
Not at all (0) – 
Almost always (5) 
771 0.64 (<0.001) 766 5.78 (3.25) 
772 How often do you 
pass urine during 
the day? 
1-6 time (0) – 
13 or more times 
(4) 
790 Over the past month, 
how often have you had 
to urinate again less 
than two hours after you 
finished urinating? 
Not at all (0) – 
Almost always (5) 
771 0.44 (<0.001) 762 5.05 (3.38) 
772 During the night, 
how many times 
do you have to get 
None (0) – 
Four or more (4) 
789 How many times did you 
typically get up to 
urinate from the time 
None (0) – 
5 times (5) 
770 0.86 (<0.001)b 770 5.85 (3.33) 
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up to urinate, on 
average? 
you went to bed until 
the time you got up in 
the morning? 
aPearson correlation coefficient (R) and corresponding p value, bDespite being the same question on almost the same scale 141 (18%) of men gave conflicting answers.  
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Table 5. Satisfaction with urodynamics (UDS) 
  Urodynamics arm Routine care arm 
 n (U:R) n(%)/ Median(IQR) n(%)/ Median(IQR) 
Number of men who received urodynamics  353 28 
ICIQ-UDS-Satisfaction 
Overall satisfaction (0-10) 297:6 10.00 (9.00, 10.00) 10.00 (10.00, 10.00) 
The test was...better than expected 302:6 152 (50%) 3 (50%) 
      ...same as expected  52 (17%) 1 (17%) 
      ...worse than expected  77 (26%) 2 (33%) 
      ...different but no better or worse  21 (7%) 0 (0%) 
Did you think the test was successful?a 282:5 275 (98%) 5 (100%) 
Knowing what you know now, would you take 
the test? b 
303:6 294 (97%) 6 (100%) 
Satisfaction with information received in the 
post? c 
293:6 260 (89%) 6 (100%) 
Satisfaction with information from the doctor? c 284:6 268 (94%) 6 (100%) 
Satisfaction with the doctor? c 277:5 274 (99%) 5 (100%) 
Satisfaction with the nurse who performed the 
test? c 
297:6 294 (99%) 6 (100%) 
Was your privacy and dignity preserved? d 298:6 294 (99%) 6 (100%) 
Satisfaction with the explanation of the results? e 293:5 261 (89%) 5 (100%) 
Would you recommend the test to 
friends/family? f 
301:6 278 (92%) 6 (100%) 
U=Urodynamics, R=Routine care, aVery, quite, somewhat or a little successful vs. unsuccessful, bDefinitely or 
probably vs. not sure, probably or definitely not, cVery-little satisfied vs. neutral or dissatisfied, dExtremely or 
moderately preserved vs. a little bit/not at all, eVery-little satisfied vs. neutral, dissatisfied or not received, 
fDefinitely or probably vs. not sure or not  
 
 
Table 6. Urodynamic (UDS) assessment findings 
  Urodynamics  Routine care 
 na Mean (SD) or n (%) na Mean (SD) or n (%) 
Filling cystometry 
Detrusor overactivity 341 179 (52%) 22 14 (64%) 
Maximum cystometric capacity (ml) 338 340.45 (159.72) 23 315.61 (143.09) 
Pressure flow study 
Voided volume (ml) 339 279.91 (144.19) 23 257.04 (156.54) 
Maximum flow rate (ml/s) 335 9.06 (4.77) 23 7.71 (3.84) 
Residual urine, in ml, (IQR)b 312 32.00 (0.00, 145.50) 20 50.00 (0.00, 127.00) 
Bladder Contractility Index (BCI) b 259 112.00 (89.00, 135.00) 17 114.00 (101.00, 121.50) 
Bladder Outlet Obstruction Index 
(BOOI) b 
302 48.10 (29.00, 70.00) 19 55.00 (23.00, 102.00) 
aThe number of men who we have data for (denominator); in the urodynamics arm, we are aware that 353 
men received UDS and in the non-UDS arm 28 men received UDS, therefore the maximum values are 353 and 
28 respectively, bAs data was skewed for these outcomes, medians and IQRs are presented
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Supplementary Material 1.  
 
Table S1. UPSTREAM urinary symptoms patient reported outcomes completed by participants at 0- (baseline), 6-, 12- and 18-months after 
randomisation 
Questionnaire Outcome/item(s) Outcome/scoring system  
IPSS: International Prostate Symptom Score [17] 1. Incomplete emptying 
2. Frequency 
3. Intermittency 
4. Urgency 
5. Weak stream 
6. Straining 
7. Nocturia 
QoL Patient’s perceived quality of life 
Urinary symptoms (qns 1-7) score: 0 to 35 with a higher score 
reflecting higher severity (e.g. 1-7 = mild; 8-19 = moderate; and 
20-35 = severe). 
 
Quality of life (QoL) due to urinary symptoms: score 0 
“Delighted” to 6 “Terrible”. 
  
   
ICIQ-MLUTS: International Consultation on Incontinence 
Modular Questionnaire – Male Lower Urinary Tract 
Symptoms (see [18]) 
1. Hesitancy 
2. Straining to continue urination 
3. Strength of stream 
4. Intermittency 
5. Incomplete emptying 
6. Urgency 
7. Urge urinary incontinence 
8. Stress urinary incontinence 
9. Unexplained urinary incontinence 
10. Nocturnal enuresis 
11. Post-micturition dribble (PMD) 
12. Nocturia 
13. Frequency 
A voiding and incontinence score were generated, as well as 
daytime and night-time frequency data; 
- Voiding scale: 0 to 20 with larger scores indicating more 
severe symptoms 
- Incontinence scale: 0 to 24 with larger scores indicating 
more severe symptoms 
- Daytime frequency (>8 times per day) 
- Nocturia (>1 times per night) 
 
   
ICIQ-MLUTSsex: International Consultation on 
Incontinence Modular Questionnaire – Male Sexual 
Matters associated with Lower Urinary Tract Symptoms 
(see [18]) 
 
1. Erections possible 
2. Orgasm possible 
3. Pain/discomfort during ejaculation 
4. Impact or urinary symptoms 
Number (%) reported for; 
- Erections (reduced or none) 
- Ejaculation (reduced or none) 
- Painful ejaculation (slight, moderate or severe pain) 
- Urinary symptoms spoilt sex life? (a little/somewhat/a lot) 
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Figure S2.1. Recruitment and allocation in the UPSTREAM trial 
 
 
Table S2.1 Overview of screening data 
 N % 
Total patients assessed for eligibility across 26 centres: 8671 - 
Of those patients SCREENED (n=8671): 
  
Considered ineligible: 5910 68% 
Considered eligible: 1482 17% 
Reasons for non-inclusion unidentified:  1279 15% 
Of those patients considered ELIGIBLE (n=1482): 
  
Declined to take part: 662 45% 
Randomised: 820 55% 
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Table S2.2. Summary of reasons why men were ineligible to take part (n=5910) 
 N % 
 
5910   
Exclusion criteria 2926 50% 
Undergoing treatment/surveillance prostate or bladder cancer 1293 44% 
Previous prostate surgery 559 19% 
Urinary retention 392 13% 
Neurological disease 302 10% 
Not willing / able to comply with essential study procedures 208 7% 
Not medically fit for surgery 172 6% 
Other reasons 2510 42% 
Medical team did not consider patient suitable for research/this study (non-
prostatic/non-bothersome LUTS; presentation required additional assessment; 
recurrent UTIs; unrelated condition) 
1068 43% 
Further details not provided  714 28% 
Patient no longer seeking treatment (or surgery) 346 14% 
Already had diagnostic assessments (e.g. UDS) and/or treatment plan is active 
(e.g. surgery/medication) 
341 14% 
Considered too young especially for surgery 35 1% 
Unable to make further contact with patient – deemed ineligible 6 0% 
Reason missing 474 8% 
 
 
Table S2.3. Summary of reasons why men who were eligible declined to take part (n=662) 
 N % 
 662   
Reasons 535 81% 
Does not want to be randomised 144 27% 
Other commitments 89 17% 
Could not decide 79 15% 
Number of visits 76 14% 
Not interested in research studies 56 10% 
Does not want urodynamics or additional tests 41 8% 
Other health issues more important 29 5% 
Number of questionnaires 16 3% 
Transport / parking issues 3 1% 
Relocating 2 0% 
Reason missing 127 19% 
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Figure S3.1. Overview of ICIQ 3-day bladder diary completion rates within the UPSTREAM 
trial at baseline.  
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